{"id":2336,"date":"2020-07-10T00:00:00","date_gmt":"2020-07-10T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2336"},"modified":"2020-07-10T00:00:00","modified_gmt":"2020-07-10T00:00:00","slug":"centogene-anuncia-el-precio-de-la-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/es\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","title":{"rendered":"CENTOGENE anuncia el precio de la oferta p\u00fablica primaria y secundaria de acciones ordinarias"},"content":{"rendered":"<p>CAMBRIDGE, Massachusetts, ROSTOCK, Alemania y BERL\u00cdN, 9 de julio de 2020 (Globe Newswire) \u2013 Centogene NV (Nasdaq: CNTG) (\u201cCentogene\u201d o la \u201cCompa\u00f1\u00eda\u201d), una empresa en fase comercial especializada en enfermedades raras que transforma datos cl\u00ednicos y gen\u00e9ticos del mundo real en informaci\u00f3n pr\u00e1ctica para pacientes, m\u00e9dicos y compa\u00f1\u00edas farmac\u00e9uticas, anunci\u00f3 hoy la fijaci\u00f3n del precio de su oferta p\u00fablica primaria y secundaria de 3.500.000 acciones ordinarias de la Compa\u00f1\u00eda, compuesta por 2.000.000 de acciones ordinarias ofrecidas por la Compa\u00f1\u00eda y 1.500.000 de acciones ordinarias ofrecidas por los accionistas vendedores a un precio al p\u00fablico de Centogene14,00 por acci\u00f3n ordinaria, lo que representa un beneficio bruto total para la Compa\u00f1\u00eda de Centogene28 millones y un beneficio bruto total para los accionistas vendedores de Centogene21 millones. La Compa\u00f1\u00eda no recibir\u00e1 ning\u00fan beneficio de la venta de acciones ordinarias por parte de los accionistas vendedores. Adem\u00e1s, los accionistas vendedores han concedido a los suscriptores una opci\u00f3n de 30 d\u00edas para comprar hasta 525.000 acciones ordinarias adicionales al precio de la oferta p\u00fablica, menos los descuentos y comisiones de suscripci\u00f3n.<\/p>\n<p>Se espera que la oferta se cierre alrededor del 14 de julio de 2020, sujeto a las condiciones de cierre habituales.<\/p>\n<p>Credit Suisse y SVB Leerink act\u00faan como gestores conjuntos de la oferta, mientras que Baird, BTIG y Kempen &amp; Co act\u00faan como cogestores.<\/p>\n<p>Centogene pretende utilizar los ingresos netos de la oferta en investigaci\u00f3n y desarrollo para apoyar el desarrollo de medicamentos hu\u00e9rfanos con su plataforma de informaci\u00f3n basada en el conocimiento, as\u00ed como para capital de trabajo y otros fines corporativos generales. Una parte de los ingresos netos tambi\u00e9n podr\u00e1 utilizarse para adquirir o invertir en negocios, activos o tecnolog\u00edas complementarios.<\/p>\n<p>La Comisi\u00f3n de Bolsa y Valores (SEC) declar\u00f3 efectiva una declaraci\u00f3n de registro relativa a estos valores el 9 de julio de 2020. La oferta se realiza \u00fanicamente mediante un prospecto. Se pueden obtener copias del prospecto final de la oferta, cuando est\u00e9n disponibles, de forma gratuita, visitando EDGAR en el sitio web de la SEC: www.sec.gov. Alternativamente, se pueden obtener copias del prospecto final, cuando est\u00e9n disponibles, de Credit Suisse Securities (USA) LLC, Atenci\u00f3n: Departamento de Prospectos, 6933 Louis Stephens Drive, Morrisville, NC 27560, por tel\u00e9fono al (800) 221-1037 o por correo electr\u00f3nico a usa.prospectus@credit-suisse.com; o de SVB Leerink LLC, Atenci\u00f3n: Departamento de Sindicatos, One Federal Street, Piso 37, Boston, MA 02110, por tel\u00e9fono al (800) 808-7525, ext. 6218 o por correo electr\u00f3nico a syndicate@svbleerink.com.<\/p>\n<p>Este comunicado de prensa no constituir\u00e1 una oferta de venta ni una solicitud de oferta de compra de estos valores, ni habr\u00e1 ninguna venta de estos valores en ning\u00fan estado o jurisdicci\u00f3n en el que dicha oferta, solicitud o venta sea ilegal antes del registro o calificaci\u00f3n seg\u00fan las leyes de valores de dicho estado o jurisdicci\u00f3n.<\/p>\n<p>\u201cEn CENTOGENE, nos enorgullecemos de ofrecer a nuestros pacientes pruebas diagn\u00f3sticas en las que pueden confiar\u201d, a\u00f1ade el Dr. Florian Vogel, vicepresidente s\u00e9nior de Operaciones de Laboratorio Cl\u00ednico. \u201cCon nuestra reciente iniciativa de pruebas de COVID-19, hemos demostrado que, incluso en tiempos de escasez de recursos, es posible desarrollar y ofrecer r\u00e1pidamente pruebas de alta calidad seg\u00fan las directrices de la OMS\/CDC.<\/p>\n<h2 class=\"h3\">Acerca de CENTOGENE<strong> <\/strong><\/h2>\n<p>CENTOGENE se dedica al diagn\u00f3stico y la investigaci\u00f3n de enfermedades raras, transformando datos cl\u00ednicos y gen\u00e9ticos del mundo real en informaci\u00f3n pr\u00e1ctica para pacientes, m\u00e9dicos y compa\u00f1\u00edas farmac\u00e9uticas. Nuestro objetivo es racionalizar las decisiones terap\u00e9uticas y acelerar el desarrollo de nuevos medicamentos hu\u00e9rfanos mediante nuestro amplio conocimiento sobre enfermedades raras, que incluye datos epidemiol\u00f3gicos y cl\u00ednicos, as\u00ed como biomarcadores innovadores. CENTOGENE ha desarrollado una plataforma global propia para enfermedades raras basada en nuestro repositorio de datos del mundo real, con aproximadamente 3.000 millones de puntos de datos ponderados de m\u00e1s de 530.000 pacientes de m\u00e1s de 120 pa\u00edses diferentes, al 31 de marzo de 2020.<\/p>\n<p>La plataforma de la Compa\u00f1\u00eda incluye datos epidemiol\u00f3gicos, fenot\u00edpicos y gen\u00e9ticos que reflejan una poblaci\u00f3n global, as\u00ed como un biobanco de muestras de sangre de estos pacientes. CENTOGENE considera que esta es la \u00fanica plataforma que analiza exhaustivamente datos multinivel para mejorar la comprensi\u00f3n de las enfermedades hereditarias raras, lo que puede facilitar la identificaci\u00f3n de pacientes y mejorar la capacidad de nuestros socios farmac\u00e9uticos para comercializar medicamentos hu\u00e9rfanos. Al 31 de marzo de 2020, la Compa\u00f1\u00eda colaboraba con 39 socios farmac\u00e9uticos que abarcaban m\u00e1s de 45 enfermedades raras diferentes.<\/p>\n<h5>Contacto:<\/h5>\n<p>CENTOGENE<br \/> Ben Legg<br \/> Comunicaciones corporativas<br \/> <a href=\"mailto:press@centogene.com\" title=\"Escribe un correo electr\u00f3nico\">press@centogene.com<\/a><\/p>\n<p>Contacto con los medios<strong> <\/strong><br \/> Consultor\u00eda FTI<br \/> Bridie Lawlor<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Escribe un correo electr\u00f3nico\">bridie.lawlor@fticonsulting.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2336","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/es\/centogene-anuncia-el-precio-de-la-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/es\/centogene-anuncia-el-precio-de-la-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-10T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares\",\"datePublished\":\"2020-07-10T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"},\"wordCount\":677,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\",\"name\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-10T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/es\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE Anuncia la Fijaci\u00f3n de Precios de la Oferta P\u00fablica Primaria y Secundaria de Acciones Ordinarias | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/es\/centogene-anuncia-el-precio-de-la-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/","og_locale":"es_ES","og_type":"article","og_title":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares | CENTOGENE","og_description":"CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (Globe Newswire) \u2013 Centogene N.V. (Nasdaq: CNTG) (\u201cCentogene\u201d or the [&hellip;]","og_url":"https:\/\/www.centogene.com\/es\/centogene-anuncia-el-precio-de-la-oferta-publica-primaria-y-secundaria-de-acciones-ordinarias\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-10T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares","datePublished":"2020-07-10T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"},"wordCount":677,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","url":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/","name":"CENTOGENE Anuncia la Fijaci\u00f3n de Precios de la Oferta P\u00fablica Primaria y Secundaria de Acciones Ordinarias | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-10T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-announces-pricing-of-primary-and-secondary-public-offering-of-common-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Impulsar la medicina de precisi\u00f3n","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"administrador","url":"https:\/\/www.centogene.com\/es\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/comments?post=2336"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2336\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/media?parent=2336"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/categories?post=2336"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/tags?post=2336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}